Griffin Securities Sees More Countries Approving Intrexon's (XON) OX513A Amid Zika Pandemic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Fibrocell Highlights Recent Pipeline Accomplishments
January 27, 2016 8:01 AM ESTPatient Dosing in Phase II Trial of azficel-T for Chronic Dysphonia Completed Preclinical Toxicology Study for FCX-007 InitiatedPositive POC Data Shows FCX-013 Reduces Dermal Thickness of Fibrotic Tissue
EXTON, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ: FCSC), an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs, today highlighted several recent accomplishments related to the continued advancement of the companys pipeline.
Recently, Fibrocell has made significant progress across our pipeline of personalized biologics, positioning the company to achieve... More
